ArticleJournal of physiology and biochemistry2025
m6A-modified circCCAR1 promotes malignant proliferation by enhancing KIF5B expression in hepatocellular carcinoma.
Article in Journal of physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is known for its aggressive nature and high mortality rates. Circular RNAs (circRNAs) have emerged as critical regulators of cancer progression, yet the role of the circRNA cell division cycle and apoptosis regulator 1 (circCCAR1) in HCC is poorly understood. This study aims to explore the mechanism of circCCAR1 in HCC progression. We measured the expression of circCCAR1, miR-641, and motor protein kinesin family member 5B (KIF5B) in HCC cell lines and normal hepatic cells, revealing that circCCAR1 was significantly overexpressed in HCC. Mechanistic analyses showed that the RNA methyltransferase YTH domain-containing protein 1 (YTHDC1) recognized N6-methyladenosine (m6A) modifications on circCCAR1, facilitating its transport from the nucleus to the cytoplasm. In the cytoplasm, circCCAR1 acted as a molecular sponge to sequester miR-641, relieving miR-641-mediated inhibition of KIF5B mRNA. CircCCAR1 directly bound to the RNA-binding protein polypyrimidine tract-binding protein 1 (PTBP1), which stabilized KIF5B mRNA. Functional experiments demonstrated that silencing circCCAR1 suppressed HCC cell proliferation, induced apoptosis, and reduced tumor growth in a xenograft mouse model, effects that were partially reversed after KIF5B overexpression or miR-641 inhibition. In conclusion, YTHDC1 promotes the cytoplasmic translocation of m6A-modified circCCAR1 and circCCAR1 facilitates HCC progression through the miR-641/KIF5B axis.
Indexed as
Identifiers
40696234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.